Keywords (1)

Academic
Publications
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis,10.1056/NEJMoa0907839,New England Journal of Medicine,Jeffrey A. Cohen,Fr

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis   (Citations: 65)
BibTex | RIS | RefWorks Download
Jeffrey A. Cohen, Frederik Barkhof, Giancarlo Comi, Hans-Peter Hartung, Bhupendra O. Khatri, Xavier Montalban, Jean Pelletier, Ruggero Capra, Paolo Gallo, Guillermo Izquierdo, Klaus Tiel-Wilck, Ana de Verahttp://academic.research.microsoft.com/io.ashx?type=5&id=30111458&selfId1=0&selfId2=0&maxNumber=12&query=
Journal: New England Journal of Medicine - N ENGL J MED , vol. 362, no. 5, pp. 402-415, 2010
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
    • ...FTY720 is an immunosuppressive drug recently approved for the treatment of multiple sclerosis ...

    Craig T. Wallington-Beddoeet al. Disparate In Vivo Efficacy of FTY720 in Xenograft Models of Philadelph...

    • ...the same eligibility criteria to evaluate fingolimod doses of 0.5 and 1.25 mg in RRMS patients in comparison to IFN-b 1a, given at a weekly dose of 30 l gi m [111]...
    • ...Serious infections were reported in 2.6 and 1.7% of patients on fingolimod 1.25 mg and in 1.6 and 0.2% of patients on fingolimod 0.5 mg in FREEDOMS and TRANSFORMS, respectively, with two fatal herpes virus infections on fingolimod 1.25 mg. While there was no signal in the FREEDOMS trial [110], eight cases of localised skin cancer occurred in fingolimod treated patients in the TRANS-FORMS trial [111] with further new cases in the extension ...

    Martin Duddyet al. Managing MS in a changing treatment landscape

    • ...After two successful phase III trials [14,15] FTY720 has been approved as the first orally available drug to treat relapsing-remitting multiple sclerosis by the FDA in 2010...

    Waltraud Pfeilschifteret al. Treatment with the immunomodulator FTY720 does not promote spontaneous...

    • ...Aiming to sample ≥20 articles per journal, we reviewed NEJM through 28 February 2010; JAMA through 10 March 2010 and Annals through 6 April 2010. The initial cohort totalled 65 articles, with 21 from NEJM, 21 from JAMA and 23 from Annals. The initial review excluded 14 articles, leaving a cohort of 51 that reported research that could be important to medical practice: 18 from NEJM,...

    Joanne Lynnet al. Clarity and strength of implications for practice in medical journal a...

    • ...The number of patients (9 of 11 patients) with RRMS showing scans with AEBLs correlated with the most recent relapse occurring within 6 months. However, the percentage of scans with AEBLs performed within 6 months after the last relapse was not different from that of scans performed more than 6 months after the last relapse. The reason why brain MRI within 6 months after the last relapse did not show more AEBLs may be due to the small number of patients who were examined more than 6 months after the last relapse.The incidence of contrast-enhancing lesions in our brain MRI study was compared with that in clinical trials for MS in Western countries that used the same enrolling criteria, including at least one relapse in the preceding year. The percentage of patients with contrast-enhancing brain lesions was 39.1% in patients with RRMS in the present study, which was similar to that in Western countries [39 and 41% before treatment (baseline period) with interferon-ß1a and glatiramer acetate, respectively (the REbif vs. Glatiramer Acetate in Relapsing MS Disease (REGARD) study] [,,,,,,,...

    Masami Tanakaet al. Low Incidence of Asymptomatic Contrast-Enhancing Brain Lesions in Japa...

Sort by: